Saturday, 31 October 2026European Markets

AUSTEVOLL SEAFOOD And SALMAR Have A High Dividend Yield And Return On Equity In The Farm Products Industry.

Loading stream...

(VIANEWS) - AUSTEVOLL SEAFOOD (AUSS.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Farm Products industry.

Financial Asset Price Forward Dividend Yield Return on Equity
AUSTEVOLL SEAFOOD (AUSS.OL) kr71.45 7.18% 15.89%
SALMAR (SALM.OL) kr566.80 3.45% 6.83%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. AUSTEVOLL SEAFOOD (AUSS.OL)

7.18% Forward Dividend Yield and 15.89% Return On Equity

Austevoll Seafood ASA, a seafood company, engages in the salmon and trout, white fish, and pelagic businesses in Norway, the European Union, the United Kingdom, Eastern Europe, Africa, North America, Asia, South America, and internationally. The company is involved in the ownership and operation of fishing vessels, as well as farming, aquaculture, processing, sale, and distribution of salmon and trout. It also produces white fish products, freezing and canning plants, fish meals, and fish oils; omega-3 oil; and canned and frozen fish products. The company was incorporated in 1981 and is headquartered in Storebø, Norway. Austevoll Seafood ASA is a subsidiary of Laco AS.

Earnings Per Share

As for profitability, AUSTEVOLL SEAFOOD has a trailing twelve months EPS of kr0.78.

PE Ratio

AUSTEVOLL SEAFOOD has a trailing twelve months price to earnings ratio of 91.6. Meaning, the purchaser of the share is investing kr91.6 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.89%.

Volume

Today's last reported volume for AUSTEVOLL SEAFOOD is 106197 which is 53.03% below its average volume of 226135.

More news about AUSTEVOLL SEAFOOD.

2. SALMAR (SALM.OL)

3.45% Forward Dividend Yield and 6.83% Return On Equity

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming, Sales & Industry, Icelandic Salmon, and SalMar Aker Ocean segments. It is involved in the broodstock, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr6.55.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 86.53. Meaning, the purchaser of the share is investing kr86.53 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.83%.

Moving Average

SALMAR's worth is above its 50-day moving average of kr553.50 and way higher than its 200-day moving average of kr487.04.

Sales Growth

SALMAR's sales growth is 40.9% for the present quarter and 8.4% for the next.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 9, 2023, the estimated forward annual dividend rate is 20 and the estimated forward annual dividend yield is 3.45%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 52.6%, now sitting on 26.41B for the twelve trailing months.

More news about SALMAR.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com